Braveheart Bio

BRVE · NASDAQ · Healthcare

$19.77

▲ $19.77 (4.49%)

1D 7D 1M 3M 1Y

Day range

$18.44 – $19.95

Year range

$17.86 – $32.00

Open

$18.92

Previous close

—

Market cap

$1.40B

Volume (24h)

$46.3K

Volume (52w)

$914.92K

Performance

▼ -7.05%

▼ -31.62%

▼ -33.66%

YTD

▼ -33.66%

All-time

▼ -33.66%

Key statistics

P/E ratio

-7.88

EPS (TTM)

$-2.51

Dividend yield

—

Dividend (TTM)

—

Payout ratio

—

Shares outstanding

70.7M

About Braveheart Bio

Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.

Visit website

Country: United States of America

LLY Eli Lilly and Company	$1179.27	0.83%
JNJ Johnson & Johnson	$261.44	1.93%
ABBV AbbVie	$276.47	1.49%
MRK Merck & Co.	$145.60	2.26%
UNH UnitedHealth Group Incorp…	$379.30	2.25%